Incident · 8-K Item 1.05
West Pharmaceutical Services reports encryption and data theft that paused global operations
Compiled from public records. Updated 2026-11-14. By the cisonews.net Desk.
West Pharmaceutical Services filed a Form 8-K under Item 1.05 with the SEC on May 11, 2026, reporting a material cybersecurity attack in which an unauthorized party exfiltrated certain data and encrypted certain systems. The filing does not say what kind of data was taken and gives no count of affected people.
Entries like this one, in Wednesday’s docket
Wednesdays
Unsubscribe any time.
What happened and when
The company says it first detected an intrusion on May 4, 2026. It reports that the response included taking systems offline worldwide, notifying law enforcement and hiring outside forensic experts.
The materiality determination came on May 7, 2026, and the report was signed May 11, 2026. The company also states it took steps meant to reduce the risk that the stolen data is spread further.
Effect on operations and finances
The original filing says the incident and the response temporarily disrupted business operations around the world. Core enterprise systems had been restored, while shipping, receiving and manufacturing had restarted at only some sites, with no final timeline for full restoration. The company said then that any material financial effect had not been determined.
What the May 20 amendment added
Amendment No. 1, signed May 20, 2026, reports that manufacturing, receiving and shipping had restarted at all sites. It adds that no unauthorized activity or access is ongoing or has been observed since May 5, 2026.
On finances, the company says it believes the incident is not reasonably likely to have a material impact on its 2026 second-quarter and full-year financial guidance.
What West's 10-Qs say the attack cost
West's two quarterly reports since the attack put numbers on the downtime. In the 10-Q for the second quarter of 2026, filed on July 23, 2026, the company says production downtime from the May incident cut its revenue growth by about $7 million.
The hit landed in West Vantage, the contract-manufacturing segment. Its gross profit margin fell 3.3 percentage points in the second quarter against the same quarter of 2025, which the company puts down to downtime inefficiencies from the incident and to inflation in plant costs, partly offset by price increases. The segment's operating profit fell $4.9 million, or 27.5%, in that quarter. By the end of September the segment's nine-month operating profit was down $9.6 million, or 17.9%, with the incident named as the main factor.
West also booked nonrecurring professional fees outside its segments. The fees cover the cyber incident together with "certain legal matters", and the filings do not split the two: $6.9 million in the second quarter, $1.8 million in the third and $9.2 million for the first nine months of 2026.
| Measure (West Vantage segment unless noted) | Period | Figure in the 10-Q |
|---|---|---|
| Revenue growth lost to production downtime (company) | Q2 2026 | About $7 million |
| Gross profit margin change | Q2 2026 | Down 3.3 points |
| Operating profit change | Q2 2026 | Down $4.9 million (27.5%) |
| Operating profit change | First nine months of 2026 | Down $9.6 million (17.9%) |
| Nonrecurring professional fees, incident and legal matters combined (company) | First nine months of 2026 | $9.2 million |
The risk-factor section of the third-quarter 10-Q adds that West carries cybersecurity insurance, without saying whether it has claimed on it or how much it has recovered.
How much did the cyberattack cost West Pharmaceutical?
West has not given one total. Its 10-Qs give about $7 million of revenue growth lost to downtime in the second quarter of 2026, and margin and profit drops in its West Vantage segment. The professional fees it reports ($9.2 million in the first nine months) also cover other legal matters.
Was patient or customer data taken?
The 8-K and the amendment say data was exfiltrated, but neither filing, nor either 10-Q, says what kind of data or whose.
Is West back to normal production?
The May 20 amendment says manufacturing, receiving and shipping had restarted at all sites.
What the documents leave open
The two 8-K filings say the investigation continues, and none of the four filings identifies the data categories involved, the number of people or customers affected, or the party responsible. None of them mentions notification letters to individuals, so readers who want to know whether their information was involved cannot learn that from these documents.
How this disclosure's timing compares
West Pharmaceutical Services disclosed 7 days after the discovery date its filing gives. Across the 46 other filings under 8-K Item 1.05 on cisonews.net that date discovery to the day, the median gap is 6 days.
The rule behind an Item 1.05 filing
Form 8-K Item 1.05 is where a public company reports a cybersecurity incident it has determined to be material. Under the rule the SEC adopted on July 26, 2023, the filing is generally due four business days after the company determines that the incident is material. Source: U.S. Securities and Exchange Commission, press release 2023-139. The guide What is SEC Form 8-K Item 1.05, and what counts as a disclosed cyber incident? reads the rule in full, and the glossary defines Form 8-K Item 1.05.
Other life sciences & medical devices incidents on cisonews.net
- Dexcom, Inc., Breach notice, first disclosed November 13, 2026
- LeMaitre Vascular, Inc., Breach notice, first disclosed September 18, 2026
- Boston Scientific, 8-K Item 1.05, first disclosed August 26, 2026
- Amgen, 8-K Item 1.05, first disclosed July 31, 2026; 39,594 affected in total (Indiana Attorney General)
- Fresenius Kabi USA, LLC, Breach notice, first disclosed June 17, 2026
Sources
- 2026-05-11 · AWest Pharmaceutical Services, Inc., Form 8-K (SEC EDGAR), published May 11, 2026
- 2026-05-20 · AWest Pharmaceutical Services, Inc., Form 8-K/A (SEC EDGAR), published May 20, 2026
- 2026-07-23 · AWest Pharmaceutical Services, Form 10-Q for the quarter ended June 30, 2026 (SEC EDGAR), published July 23, 2026
- 2026-10-29 · AWest Pharmaceutical Services, Form 10-Q for the quarter ended September 30, 2026 (SEC EDGAR), published October 29, 2026
- 2023-07-26 · AU.S. Securities and Exchange Commission, press release 2023-139, published July 26, 2023
Tier A: the organization itself (including notices it filed with a state attorney general), a regulator or SEC EDGAR. Tier B: established press. Each fact on this page carries its supporting passage in the page source.
Entries like this one, in Wednesday’s docket
Wednesdays
Unsubscribe any time.